AMAG Pharmaceuticals Inc (AMAG)-Medical Equipment-Deals and Alliances Profile

AMAG Pharmaceuticals Inc (AMAG)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME3552D
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in women, Feraheme (ferumoxytol) for iron deficiency anemia in adult patients with chronic kidney disease and MuGard Oral Mucoadhesive for the management of oral mucositis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers these products through direct sales and a network of distributors. It has presence in the US, Switzerland and the UK. AMAG is headquartered in Waltham, Massachusetts, the US.

AMAG Pharmaceuticals Inc (AMAG)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company financial deals that enable you to understand the company expansion/divestiture and fund requirements

The profile enables you to analyze the company financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company business segments' expansion / divestiture strategy

The profile presents deals from the company core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

AMAG Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9

AMAG Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

AMAG Pharmaceuticals Inc, Medical Equipment, Deal Details 11

Private Equity 11

MSMB Capital Management To Acquire AMAG Pharma 11

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 12

Equity Offering 13

AMAG Pharma Raises USD231 Million in Public Offering of Shares 13

Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 14

Debt Offering 15

AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 15

AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 17

Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 17

Acquisition 19

AMAG Pharma Plans For Sale Of The Company 19

AMAG Pharmaceuticals Inc-Key Competitors 21

Key Employees 22

Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 25

Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 27

Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 30

Nov 03, 2016: AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 32

Aug 09, 2016: AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 34

May 03, 2016: AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results 36

Feb 17, 2016: AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 38

Jan 11, 2016: AMAG Pharmaceuticals Announces Preliminary 2015 Financial Results and Provides 2016 Financial Guidance 40

Corporate Communications 41

May 16, 2017: AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs 41

Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 42

Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 43

Dec 21, 2016: AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors 44

Sep 07, 2016: AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales and Marketing 45

Jul 12, 2016: AMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts 46

Apr 11, 2016: AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer 47

Jan 04, 2016: AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer 48

Other Significant Developments 49

Jul 15, 2016: PhRMA Welcomes Five New Member Companies 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

AMAG Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

AMAG Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

AMAG Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

List of Tables

AMAG Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 1

AMAG Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

AMAG Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

AMAG Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 9

AMAG Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

MSMB Capital Management To Acquire AMAG Pharma 11

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 12

AMAG Pharma Raises USD231 Million in Public Offering of Shares 13

Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 14

AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 15

AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 17

Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 17

AMAG Pharma Plans For Sale Of The Company 19

AMAG Pharmaceuticals Inc, Key Competitors 21

AMAG Pharmaceuticals Inc, Key Employees 22

AMAG Pharmaceuticals Inc, Other Locations 24

AMAG Pharmaceuticals Inc, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AMAG Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16145
Site License
USD 500 INR 32290
Corporate User License
USD 750 INR 48435

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com